Covaris, Inc. Introduces DNA Shearing Service

WOBURN, Mass., April 2 /PRNewswire/ -- Covaris Incorporated today announced the introduction of DNA shearing service using Covaris instruments and technology.

Over the past few years, Covaris instruments have become the gold standard for DNA shearing application, as a sample preparation step for next generation sequencing. The Covaris process is validated and compatible with all next-gen sequencing platforms. This process is highly reproducible and gives narrow size distribution. The isothermal, non-contact processing, in closed vessels, results in high recovery and no cross contamination, which are critical for any sequencing applications downstream.

"With the launch of our DNA shearing service, researchers can immediately take advantage of our technology without having to purchase the instrument first," said Jim Laugharn, President and CEO of Covaris, "the service is ideal for several groups of customers--those who only need to process small amount of samples periodically; those who are waiting for capital budget approval for instrument purchase, and those who just want to evaluate the technology without long-term commitment. For these investigators, the DNA shearing service is a cost-effective way to "test drive" the Covaris AFA technology."

The Covaris technology foundation is its proprietary and patented AFA (Adaptive Focused Acoustics(TM)) technology. The Covaris AFA technology enables numerous non-contact, isothermal processes to be developed, for use in a broad range of applications in Genomics, Proteomics and Drug Discovery research, which could not be obtained prior to the development of AFA technology.

The DNA shearing service is a nice alternative sample prep tool for next-gen sequencing customers. In addition, Covaris is introducing eCommerce capability on Covaris website. This will enable customers to order commonly used consumables directly online.

About Covaris, Inc.

Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more.

Information about Covaris is available at http://www.covarisinc.com.

CONTACT: Jennifer Wu of Covaris, Inc., +1-781-932-3959, fax
+1-781-932-8705, jwu@covarisinc.com

Web site: http://www.covarisinc.com/

Back to news